Viking sets sail with 5 Ligand assets
This article was originally published in Scrip
Executive Summary
Viking Therapeutics licensed five assets from Ligand Pharmaceuticals, including a clinical-stage type 2 diabetes program that the private San Diego-based company has been working on since it was founded in late 2012.